AUTHOR=Zhang Chuan-Long , Fan Kui , Gao Meng-Qi , Pang Bo 

TITLE=Prognostic Value of Glasgow Prognostic Score in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 28 - 2022

YEAR=2022

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2022.1610109

DOI=10.3389/pore.2022.1610109

ISSN=1532-2807

ABSTRACT=Background: Systemic inflammation is a key factor in tumor growth. The Glasgow Prognostic Score (GPS) has a certain value in predicting the prognosis of lung cancer. However, these results still do not have a unified direction.
Methods: A systematic review and meta-analysis were performed to investigate the relationship between GPS and the prognosis of patients with non-small cell lung cancer (NSCLC). We set patients as follows: GPS=0 vs GPS=1 or 2, GPS=0 vs GPS=1,GPS=0 vs GPS=2. We collected the hazard ratio (HR) and the 95% confidence interval (CI). 
Results: A total of 21 studies were included, involving 7333 patients. We observed a significant correlation with GPS and poor OS in NSCLC patients (HRGPS=0 vs GPS=1 or 2=1.62, 95% CI:1.27-2.07, P≤0.001; HRGPS=0 vs GPS=1=2.14, 95% CI:1.31-3.49, P≤0.001; HRGPS=0 vs GPS=2=2.64, 95% CI:1.45-4.82, P≤0.001). Moreover, we made a subgroup analysis of surgery and stage. The results showed that when divided into GPS=0 group and GPS=1 or 2 group, the effect of high GPS on OS was more obvious in surgery (HR=1.79, 95% CI:1.08-2.97, P=0.024). When GPS was divided into two groups (GPS=0 and GPS=1 or 2), the III-IV stage, higher GPS is associated with poor OS (HR=1.73, 95% CI:1.43-2.09, P≤0.001). In the comparison of GPS=0 and GPS=1 group (HR=1.56, 95% CI:1.05-2.31, P=0.026) and the grouping of GPS=0 and GPS=2(HR=2.23, 95% CI:1.17-4.26, P=0.015), we came to the same conclusion.
Conclusions: For patients with NSCLC, higher GPS is associated with poor prognosis, and GPS may be a reliable prognostic indicator. The decrease of GPS after pretreatment may be an effective way to improve the prognosis of NSCLC.